Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

The Republic of Gadgets – America’s Great Inventors – 25 Resources for K-12 Education

Understanding the enduring public and private benefit that great inventors and their contraptions have made to our civilization is to better appreciate the connections between human necessity, creativity, and ingenuity. Yet, in American K-12 education very little focus is placed on studying who America’s great inventors were and the central role they’ve played in shaping our republic of gadgets. We’re offering a variety of links on the topic for parents, teachers, and schoolchildren to enjoy and better realize authentic innovators.

Cheryl Brown Henderson, Daughter of Lead Plaintiff in Brown v. Board of Ed., on Race & Schooling

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Cheryl Brown Henderson, president of the Brown Foundation for Educational Equity, Excellence, and Research. She shares her experience as the daughter of the lead plaintiff in the landmark U.S. Supreme Court case, Brown v. Board of Education of Topeka, Kansas, and thoughts on how the historic decision contributed to advancing civil rights in our country.

The Houses of Great American Writers – 25 Resources for K-12 Education

According to the Brookings Institution research, teaching great fiction is declining across America’s K-12 education system, so we’re offering resources to help parents, teachers, and schoolchildren to better appreciate great American writers and the places where they wrote.

Getting Nursing Home Care Right

Pioneer Institute has long recognized that seniors deserve the best of care and that innovative policy solutions are necessary to ensure that this population enjoys a high quality of life in their later years. In the 1990s, early 2000s and most recently in 2017, the Institute dedicated Better Government Competition topics to policy issues related to aging in America. Our goal each time was to find solutions and to take advantage of new innovations that would improve the quality of life and care for the elderly.

Harvard PEPG’s Prof. Paul Peterson on Charter Schools, Digital Learning, & Ed Next Polling

This week on “The Learning Curve,” Cara and Gerard are joined by Paul Peterson, the Henry Lee Shattuck Professor of Government and Director of the Program on Education Policy and Governance at Harvard University.

Small Business Life Support: Policy Relief for Firms Sickened by COVID?

0 Comments
/
Host Joe Selvaggi talks with Pioneer Institute’s Andrew Mikula and Retailers Association of Massachusetts' Jon Hurst about the state of small business in Massachusetts six months into the pandemic.

A Commonwealth of Art – 20 Resources for K-12 Art Education

In Pioneer’s ongoing series of blogs here, here, here, and here on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Introducing K-12 schoolchildren to great works of art about, from, or in Massachusetts. Great Massachusetts paintings, folk, and fine arts are often not fully explored in the Bay State’s K-12 education system, so we’re offering a variety of resources to help parents, teachers, and schoolchildren.

Award-Winning Writer Brenda Wineapple on the 170th Anniv. of The Scarlet Letter & Pres. Andrew Johnson’s Impeachment

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Brenda Wineapple, author of the award-winning Hawthorne: A Life and The Impeachers: The Trial of Andrew Johnson and the Dream of a Just Nation. They discuss her definitive biography of Nathaniel Hawthorne and the 170th anniversary of the publication of his classic novel, The Scarlet Letter.

Study: Economic Recovery from COVID Will Require Short-Term Relief, Long-Term Reforms

As the initial economic recovery from the COVID-19 pandemic has slowed, a new study from Pioneer Institute finds that governments must continue to provide short-term relief to stabilize small businesses as they simultaneously consider longer-term reforms to hasten and bolster recovery – all while facing a need to shore up public sector revenues.

International Best-Seller Dr. Jung Chang On Wild Swans, Mao’s Tyranny, & Modern China

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Dr. Jung Chang, author of the best-selling books Wild Swans: Three Daughters of China; Mao: The Unknown Story; and Big Sister, Little Sister, Red Sister: Three Women at the Heart of Twentieth-Century China.

“Architecture is Frozen Music” Great Massachusetts Buildings – 25 Resources for K-12 Education

Understanding enduring public and private architecture is a key way to learn about art, ideas, and how they harmonize with our democracy. Yet, Massachusetts buildings are often never discussed in K-12 education. We’re offering a variety of links about outstanding houses and architecture across the Bay State for parents, teachers, and schoolchildren to enjoy, visit, and better appreciate, including:

COVID-19 Transparency – A Step Backwards

0 Comments
/
Massachusetts has unfortunately taken the backwards step of ending its longstanding daily reporting of something basic and important: the virus’s cumulative impact on various age groups.